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Abstract 
As hypertension becomes more prevalent 1n the pediatnc population, 
clinrcrans are more likely to encounter hypertensive emergencies in 
children, which require pharmacists and physicians to be educated 
on the therapeubC options for these emergencies. However, the 
stnct governmental requirements on the testing of these drugs in 
ped1atnc pabents have limited the amount of available evidence on 
which to base chmcal dec1s1ons. This review will highlight the avail-
able evidence and preferred treatment options for the management 
of pedratnc hypertensive emergencies. 
Introduction 
Histoncally only a disease of adults, hypertension 1s increasing in 
the pedratnc populatlOn. Recent studies show that the prevalence of 
hypertens10n in school-age children 1s about 4-5 percent 1 In children, 
hypertens10n is defined as systolic blood pressure and/or drastolic blood 
pressure greater than the 95th percentile for sex, age and height on at 
least three occasions 2 In contrast to hypertension in adults, which is 
usually pnmary, hypertens10n in children 1s commonly due to second-
ary causes such as renal disease. card10vascular disease, endocrine 
disorders and med.:atlOns 1 
Little data is available on the use of ant1hypertensive medrcauons in 
children due to ethlC81 concerns and stnct testing requirements for the 
ped1atnc populaoon.' With continued research and clinical expenence, 
chmc1ans will have more evidence to guide decisions and select the 
most appropriate and efficacious medication. Pract1t1oner fam1lianty 
with the pediatric population and available treatments for hypertensive 
emergencies will opumrze patient outcomes. This review will present the 
possible medicatJon opuons for the treatment of hypertens ive emergen-
cies 1n the pedra.tnc population, with a focus on the dose, route of ad-
mimstratJOn and other charactenst1cs specific to each drug. Furthermore, 
roles for pharmacists 1n the prevenllon and treatment of these severe 
hypertensive episodes in pedratric patients will be discussed. 
Severe Hypertension 
Severe hypertens10n in children IS defined as a blood pressure above 
the 99th percentile 3 Hypertensive emergency can be identified by 
the presence of acute end-organ dysfunction Clinical presenration of 
end-organ damage involve the central nervous system. eyes, heart, 
and kidneys and may manifest as se1Zures, ret1nopathy, card10megaly, 
congesbve heart failure, tachypnea, and/or lethargy, among other pre-
sentaoons •The type of acute end-organ damage determines the type of 
therapy used to treat these paaen:s. 
Pharrnacotherapy for Hypertensive Emergencies 
Hypertensive emergencies require 1mmed1ate treatment Several fac-
tors dictate which treatment option will be utilized, including the severity 
of the pabent's chnrcal condition, type of end-organ damage, presumed 
cause, cardrac output, total peripheral resistance, and physician 
familiarity with the medications. 5 Hypertensive emergency is typically 
treated using intravenous (IV) medications to closely control reductions 
in blood pressure. The goal of treatment IS to decrease blood pres-
sure by up to 25 percent over the first six to eight hours, followed by a 
gradual reduction over the next 48 hours.5-7 Treatment of hypertensive 
emergencies requires a controlled decrease in blood pressure to avoid 
severe hypotens1on, which may result 1n 1Schem1a and necros1S due to 
changes 1n 11ssue autoregulat1on.5 
Sodium mtropruss1de 
Sodium mtropruss1de is an arteriolar and venous vasod1lator with an 
instantaneous onset of action.5 Th IS advantage IS somewhat offset by 
its 10-mmute preparatlOn time. The vial must be recorisbtuted with 5 
percent dextrose in water or stenle water and then further diluted for 
continuous mfus10n vra a volumetnc infusion pump to allow for tightly 
controlled admin1Strat10n.' Additionally, the bo:lle, burette and syringe 
pump must be covered with an opaque protectJve covering to prevent 
degradauon by light. amber plastic covenngs are insufficient Sodium 
nrtroprusslde decreases both cardiac preload and afterload with no 
chronotropte or motroprc effects. 7 It may be used when short-term re-
ductlOn of cardiac pre load and/or afterload IS desired.' Cyanide toxicity 
1s a concern with mtropruss1de, and, according to manufacturer recom-
mendaoons, failure to obtain the desired blood pressure control after 
maximum rate infusion (8-10 mcg/kg/m1n) for 10 minutes should result 
in termination of the infusion to avoid toxic cyanide levels.' Patients 
with hepatJc or kidney dysfunction a re more prone to accumulation of 
thiocyanate, and anunc pa tients should receive no more than 1 mcg/kg/ 
min to avoid toxicity. Signs of cyanide tox1c1ty may not appear until an 
hour after toxic levels have been reached. Administraoon of thiosulfate 
and methylene blue have been postulated as rreatments for cyanide 
toxicity. but these should be used with caution as their routine use is not 
recommended. Nitropruss1de may increase intracranial pressure and 
should not be used to treat compensatory hy~rtens10n due to aortic 
coarctauon or artenovenous shunting in patients with known inadequate 
cerebral c1rculabon, or high-output heart failure'' 
Nllroglycenn 
Nitroglycenn IS a potent vasodllator that reduces blood pressure by 
predominately decreasing preload and modestly reducing afterload.' 10 It 
IS mainly used as an adjunct in patients with hypertensive emergencies 
associated wrth acute coronary syndromes or acute pulmonary syn-
dromes." Its use IS contraindicated 1n pencard1al tamponade, restncbve 
card10myopathy and constrictive paricard1t1s.6 The onset of action is 
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one to five minutes with a duratior of action of five to 10 minutes after 
the infusion is d1scontmued.9 Despite its favorable onset and duration, 
nitroglycenn is not considered a first-Ima treatment because of its poten-
tia l to cause tachycardia and precipitous hypotens1on even m very small 
doses." Methemoglobmem1a has been observed in adults when doses 
greater than 7 mcg/kg/mm were used; tachyphylaxis also has been 
seen i11 adullli am.I can often be reversed t.Jy an eiy l1t-l1uur 11ilrate-free 
interval.6 The infusion should be administered from a glass bottle using 
a non-polyvinyl chloride (PVC) set to prevent drug adsorption to the 
tubing. If a PVC set must be used, higher than expected doses may be 
required due to loss of drug in the tubing. 6 
Labeta/ot 
Labetalol is a selective a 1 and non-selective 13-blocker. It has an onset 
of action withm two to five minute~ and can be administered as an 
intermittent or continuous mfus1on.5~ Because la beta Joi is not cardiose-
lective, 1t reduces blood pressure by producing both a modest reduction 
in heart rate and a decreased systemic resistance through vasodila-
tion.7 It may be a safe chot0e 1n patients with cerebrovascular disease 
or increased mtracranial pressure because it does not further increase 
cerebral blood flow or mtracrarnal pressure.4 Labetalol 1s contraindicated 
in asthma, chron1C lung disease, heart block, cardiogenic shock and 
heart failure. Dose adjustments are not required in patients with severe 
renal or hepallc dysfunction. 5 Like other 13-blockers, labetalol may mask 
symptoms of hypoglycemia such as tachycardia.7 If using labetalol in a 
patient suspected of pheochromocytoma or stimulant intoxication, spe-
cific assay methods such as high-performance liquid chromatography 
with solid-phase extraction should be used to avoid false-positive urine 
catecholamine tests. Additionally, la be ta Joi may produce false positives if 
using the Toxt-Lab A or Emit-d.a.L. amphetamine assays.6 
Esmo/ol 
In contrast to the non-selective 13-blocker labetalol , esmolol is a 131 
selective receptor amagomst that has an onset of action within sec-
onds.4·12 A significant advantage of esmolol is its short duration of action, 
approximately 10 to 20 minutes , and its extremely short half-lrfe, whteh 
allows 1t to be easily btrated. Esmolol reduces blood pressure by de-
creasmg cardiac output 13 It 1s thus contraindicated in sinus bradycardta, 
in a greater than first-degree heart block unless a functional pacemaker 
is in place, card1ogenk: shock and overt heart failure. 6 Esmolol is safer 
than labetalol in patients with asthma and obstructive lung disease but 
should still be avoided; if necessary, the smallest dose possible should 
be utilized.7 Like labetalol, esmolol does not increase cerebral pressure 
or blood flow.'3 ltdoes not require dose adjustments in renal or hepatic 
disease, although the half-life of the active metabolite may be increased 
tenfold in organ dysfunction.67 Esmolol is more likely to cause thrombo-
phlebitis and irritatJon when infused at concentrations greater than 10 
mg/ml, and it may interfere with glucose and cl1olesterol tes ts.6 
Hydratazine 
Hydralazine is an arteriolar vasodilator with an onset of action of 30 
minutes.5 The durabon 1s fairly unpredictable and may range from 
four to 12 hours.7 Hydralazme 1s not as potent as sodium nttroprus-
s1de and may cause reflex tachycardia requiring administration of a 
13-blocker.5 If a 13-blocker and hydralazme are used simultaneously, the 
dose requrre1nents or t1yuralazine a1e reduced.6 Tl1is drug can produce 
renin-mediated sodium and fluid retention, which may necessitate the 
use of d1uret1cs.6.7 A umque feature of hydralazme 1s that it may be given 
intramuscularly to a patient who does not have an mtravenous line 
estabhshed but requires immediate treatment.7 It also can be grven by 
IV push. Hydralazme should be used with caution m patients who have 
suffered a cerebrovascular accident.6 It is comramdicatecl in patients 
wiU1 coronary artery <.Jisease ar1<.J niitral valvular rheurnatic heart <.J1sease. 
Especially in slow acetylators , hydralazine has the rare potential to 
irlduce systemic lupus erythematosus and related syndromes such as 
glomerulonephritis; if these develop, therapy with the agent should be 
re-evaluated. Hydralazine does require dose adjustments for patients in 
renal failure and further adjustments may be made if acetylator status 
is known. It should never be diluted in sugar-containing solutions due to 
the formation of toxic hydrazones. Peripheral neuritis may develop and 
may be treated with pyridoxine. 
Nifedipine 
N1fed1pine is a calcium channel blocker admmistered sublmgually 
and has an onset of action within 15-30 minutes.5·11 ThlS drug has the 
potential to produce a precipitous drop in blood pressure, which has 
made its use controversial. It is considered safer in children than 1t is m 
adults, and usmg a dose below 0.25 mg/kg may help m1mmrze the risk of 
hypotension.13·14 
Nicardipine 
Nicardipine is also a calcium channel blocker.5 It has a favorable onset 
of action within minutes. 4~ Nicardipine is an excellent medication for 
emergencies because it can be easily prepared arid titrated, although it 
can only be given by continuous IV infusion.5•6 It has been shown to be 
safe and effective in treating hypertensive emergencies in children and 
to be as effective as nitroprusside in adults without the risk of cyanide 
toxicity.13 Nicardipine is quite selective for the peripheral vasculature. It 
produces vasodilation of cerebral and coronary vessels with little effect 
on !he heart, although there is a small chance of reduced heart rate. 
Thus, this medication is contramdicated 1n patients with advanced aortic 
stenosis and the manufacturer recommends caution in patients with 
heart failure and left ventricular dysfunct.1on, especially when concomi-
tant 13-blockers are administered.6 A few reports of reflex tachycardia do 
exist7 Propranolol has been used to treat reflex tachycardia, but caution 
must be used to avoid hypotension.6 In contrast to labetalol, nicardipine 
may be safely used in patients with bronchospastic diseases.7 There 
have been reports of thrombophlebitis when given through peripheral IV ; 
if administering by this route, rotating sites every 12 hours may reduce 
the risk of thrombophlebitis. 13 The normal concentration for administra-
tion by peripheral IV is 0.1 mg/ml; higher concentrations up to 3.6 mg! 
ml have been given safely via central lines.6 Another disadvantage of 
nicardipme is that it may cause an increase in intracranial arid intra-
ocular pressure; its use is thus discouraged in patients with suspected 
intracranial masses or space-occupying lesions.7•13 Although oo specific 
dosmg recommendations exist for use in rena or hepatic failure, conser-
vaave doses are recommended.6 
Fenoldopam 
Fenoldopam 1s a dopamme 01 receptor agomst that causes vasod1lat1on 
of coronary, cerebral, renal and splanchnic vasculature, leadmg to a 
dose-dependent decrease in blood pressure.'' It also t1as been associ-
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ated with short-term increases in urine output and creatinine clearance . ., 
There are some reports of reflex tachycardia with large doses. in some 
pediatric pauents, the tachycardia lasted four hours or more.6 Doses 
greater than 1.2 mcg/kgfmm intravenously have been associated with 
greater tachycardia without greater hypotensive effect.7 No dose adJUsl-
ments are required m renal or hepatic dysfunction. Notably, the dosage 
ranye ror rerroldoparn in chilu1err is siyrri ricarrtly t1iyl1er ll1an the auult 
range, suggesting that fenoldopam may have lower efficacy in children 
than in adults. There are reports of hypokalemia and increased intracra-
nial and intraocular pressure in adults. 6•7•13 When used for longer than 
48 hours, tolerance may develop. 13 In adults, fenoldopam was shown 
to have similar efficacy and safety as nitroprusside in the treatment of 
hypertensive crisis but was much more costly; however, fenoldopam 
has no risk of cyanide toxicity. Concomitant use with 13-blockers should 
be avoided to reduce the chance of severe hypotension as 13-blockers 
inhibit the sympathetic reflex response to fenoldopam.6 
Enalapritat 
Enalapnlat is an angiotensm converting enzyme inhibitor (ACE-I) that 
is useful in remn-dependent hypertension.7 Enalaprilat may be given by 
either IV push or intermittent infusion but is not appropriate for use in a 
continuous mfusion.6 Its use is contraindicated in patients with a history 
of angioedema due to ACE-ls and hereditary or idiopathic angioedema 
because anaphylacto1d reactions requiring immediate airway manage-
ment have occurred.6 Enalaprilat can be difficult to titrate due to its slow, 
hour-long onset and extended duration.15 This medication also has the 
potential to cause renal failure, especially in the neonate in whom the 
drug is eliminated more slowly and has an extended duration of aclion.6.7 
It requires dose ad;istment in renal failure.6 Clinicians should be aware 
that the formulation contains benzyl alcohol, which has been associated 
with the Gasping Syndrome (metabolic acidosis progressing to respira-
tory distress and gasping respirations). Transient hyperkalemia has 
been observed in adults. 
Role of Pharmacists 
Pharmacists can play an acnve role 1n both preventing and treating 
hypertensive emergencies in pediatrics. In the community setting, they 
can play a proactive role by counseling the parents of pediatric patients, 
especially those with hypertension, on the importance of adherence, 
possible drug mteracuons (especially with monoam1ne ox1dase inhibi-
tors) and other concerns with the different classes of drugs. For pediatric 
patients diagnosed with hypertension, the pharmacist can monitor 
blood pressure by performing blood pressure checks between physician 
aµpointrnerrts. Tl1e ptrannacist shoulu errsure ll1e use or U1e µroper curr 
size to prevent errors in measurement. Pharmacists can also educate 
parents on poison prevention safety to avoid accidental ingestion of 
drugs that may cause hypertensive emergencies. 
Health-system pharmacists can develop guidelines to facilitate optimal 
treatment of pediatric patients with hypertensive emergencies. They can 
take complete medication histories to identify drug-related causes of 
hypertensive emergencies and assist in the selection and modification of 
therapy. They should also ensure that proper weights, heights, and renal 
and hepatic function have been documented to ensure accurate dosing.7 
Conclusion 
Ped1atnc hypertension has become more prevalent within the last 
decade. There are many possible causes of hypertension in this popula-
tJon. Patients can present with hypertensive urgency or emergency, 
which are differentiated by the presence of acute end-organ dysfunction 
and are treated accordingly. There are many different agents used in the 
treatment of hypertensive emergencies with the maj:>rity of them being 
administered parenterally with a rapid onset o' action and easy titration 
to prevent hypotension. The treatment of hypertensive emergencies 
in pediatric populations has not been extensively studied due to strict 
testing guidelines. This leaves a great deal of room for advancements in 
therapy options for pediatric hypertensive emergencies, as current treat-
ment is generally guided by experience and expert consensus. Optimal 
treatment of children with hypertensive emergencies may be impaired 
by unfamiliarity with available agents and paucity of evidence on which 
to base chmcal decisions. Pharmacists and ocher clinicians must be 
cognizant of the spec1a I issues involved 1n treating pediatnc patients and 
familiar with best practices to ensure the safe and appropriate treatment 
of pediatric patients with severe hypertension. 
Table 1: Common Medications tor the Treatment ot Pediatric Hypertensive Emergencies 
Generic Drug Name Mechanism ot Action Dose Route Onset ot Action Duration ot Action 
Sodium Vasodilator 0.25-10 mcglkg/min Continoous IV infusion Within seconds 1-lOmin 
tfrtroi:xusside"' 
Nitroglycerin'-' Vasodilator 0.25-10 mcglkg/min Continoous IV infusion 1-5min 5-lOmin 
Laretalol"'-' a1 and non-selective 0.25-1 mgfkgihr (l:xllus) or IV oolus or continuous IV 2-5min 2-4 hr 
13-adrenergic blocker 0.25-3 mg/kg/hr (continoous) infusion 
Esmoio!<·'·" 131 selective 13-blocker 500-600 mcg/kg loadingcbse, Continoous IV infusion Immediate 10-30 min then I00-500 mcglkglmin 
Hydralazinew Vasodilator 0.2-0.6 mg/kg every 4 hr IV 5-30 min 2-6 hr 
N1fed1pine'" • H Calcium channel blocker 0.2-0.5 mglkglcbse Peroral 5-15mm 8 hr 
Nicarc:t1p1ne•u Calcium channel blocker t-5 mcglkgtmin Conllnoous IV infusion Wnhin minutes 4-6 hr 
Fenok:lo1'.9JTt·'·' D 1 receptor agonist 0.2-0 8 m::glkgtm1n Con11noous IV infusion 5mm 30-60 mm 
Enalaprilat"'·'' Angiotensin converting 5-10 mcglkg/cbse IV push or intermittent IV 1 hr 24 hr 
enzyrre inhibi1or infusion 
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